A carregar...
Publicação
Tratamento de micoses fungóides : papel do farmacêutico no desenvolvimento farmacotécnico
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.11 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
Micoses Fungóides é o linfoma cutâneo das células T de maior prevalência em todo o Mundo. Manifesta-se inicialmente na pele, onde permanece durante anos ou até mesmo décadas e, com a progressão da doença, pode disseminar-se pelo organismo. Dado que a disponibilidade de opções terapêuticas se encontra muito limitada e que as aprovadas são de elevada toxicidade, muitos dos fármacos são usados off-label em formulações tópicas, sobretudo nas fases iniciais desta patologia.
O principal objectivo desta revisão bibliográfica consiste na identificação das várias contribuições que o farmacêutico - em particular, o farmacêutico hospitalar - pode fornecer para apresentar alternativas terapêuticas que controlem a progressão desta doença. Através de várias pesquisas na base de dados da PubMed e no Google Académico, foi possível identificar que o papel do farmacêutico no desenvolvimento farmacotécnico incide principalmente no desenvolvimento de formulações que consigam controlar as manchas e placas da pele, com fármacos que revelaram eficácia em ensaios clínicos descritos na literatura. Tudo isto com a preocupação da diminuição da sua toxicidade sistémica e hipersensibilidade cutânea, a fim de promover uma boa adesão à terapêutica. Para além disso, ainda envolve um grande trabalho de pesquisa, sobretudo quando a doença se mostra refractária às terapêuticas convencionais.
Mycosis Fungoides is the Cutaneous Lymphoma of T-cells (CTCL) of higher prevalence around the world. It manifests itself initially on the skin, where it remains for years or even decades and, with the progression of the disease, it can spread throughout the body. Given that the availability of treatment options are very limited and that the ones approved have high toxicity, many of the drugs are used off-label in topical formulations, especially in the early stages of this pathology. The main aim of this literature review is to identify the various contributions that the pharmacist - in particular, the hospital pharmacist - can provide to present therapeutic alternatives that control the progression of this disease. Through various searches in PubMed database and in Google Scholar, it was possible to identify the role of the pharmacist in pharmacotechnical development focuses primarily on the development of formulations that can control the skin patches and plates with drugs that have proven effective in clinical trials described in the literature. All this with the concern of decrease in systemic toxicity and cutaneous hypersensitivity, in order to promote a good adhesion to therapy. In addition, it still involves a great deal of research, especially when the disease is refractory to conventional therapies shows.
Mycosis Fungoides is the Cutaneous Lymphoma of T-cells (CTCL) of higher prevalence around the world. It manifests itself initially on the skin, where it remains for years or even decades and, with the progression of the disease, it can spread throughout the body. Given that the availability of treatment options are very limited and that the ones approved have high toxicity, many of the drugs are used off-label in topical formulations, especially in the early stages of this pathology. The main aim of this literature review is to identify the various contributions that the pharmacist - in particular, the hospital pharmacist - can provide to present therapeutic alternatives that control the progression of this disease. Through various searches in PubMed database and in Google Scholar, it was possible to identify the role of the pharmacist in pharmacotechnical development focuses primarily on the development of formulations that can control the skin patches and plates with drugs that have proven effective in clinical trials described in the literature. All this with the concern of decrease in systemic toxicity and cutaneous hypersensitivity, in order to promote a good adhesion to therapy. In addition, it still involves a great deal of research, especially when the disease is refractory to conventional therapies shows.
Descrição
Trabalho Final de Mestrado Integrado, Ciências Farmacêuticas, Universidade de Lisboa, Faculdade de Farmácia, 2013
Palavras-chave
Micoses Fungóides Terapêutica Formulações tópicas Toxicidade sistémica Hipersensibilidade cutânea Adesão à terapêutica Mestrado Integrado - 2013